Back to Search Start Over

Prevalence and outcome of Lassa fever among hospitalized patients in Ebonyi State, Nigeria, 2018-2019.

Authors :
Nwafor IE
Ogah OE
Ojide CK
Odeh EC
Abu AM
Chika-Igwenyi NM
Nwidi DU
Unigwe US
Ajayi NA
Eke MAS
Obasi MN
Adeke AS
Onyia V
Duruiheoma R
Igboke NC
Otti J
Ogbu O
Source :
Virus research [Virus Res] 2020 Aug; Vol. 285, pp. 198000. Date of Electronic Publication: 2020 May 04.
Publication Year :
2020

Abstract

Lassa fever (LF) is a viral hemorrhagic illness endemic in West Africa. Annually, about 300,000-500,000 people are being infected, with about 5000 deaths. Symptoms of LF include high grade fever, headache, malaise, abdominal pain, vomiting, diarrhea, or sore throat. Terminal features may include bleeding from all orifices (mouth, nose, ear, anus and vagina), facial and neck oedema or pleural effusion. People of all ages, gender, and occupations were included in this study. A total of 440 patients' samples and Bio data were used for this study. The samples were analyzed for Lassa fever virus RNA using Real Time Reverse Transcriptase Polymerase Chain Reaction. The data obtained were analyzed using SPSS 20.0 and version 7 of Epi-Info statistical software. Analysis of these samples showed LASV prevalence of 25.7%. Chi-square analysis (p ≤ 0.05) showed that LASV infection does not depend on age, gender, or occupation. Our research re-emphasized the fact that LASV is a serious cause of fatality in humans. Our data showed that among 327 negative patients, 19 died. On the contrary, 113 LASV confirmed positive cases had 42 deaths. This result is highly significant. More so, Lassa fever disease outcome was compared across gender. There was no significant difference between the two genders. Death or recovery from LF infection does not depend on sex. However, recovery from LF significantly depends on age of the patient. Fatal outcome is significantly higher among adults/elderly. We aim to raise awareness to the recurrence of LASV in Ebonyi State and urgent need for other medical interventions, including other therapeutic measures, and possible vaccine production, considering the impact of this virus.<br />Competing Interests: Declaration of Competing Interest The authors declared no conflict of interests.<br /> (Copyright © 2020 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1872-7492
Volume :
285
Database :
MEDLINE
Journal :
Virus research
Publication Type :
Academic Journal
Accession number :
32380207
Full Text :
https://doi.org/10.1016/j.virusres.2020.198000